|
|||
|
Multiple Sclerosis Info
|
Wednesday, February 6
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
by
All About MS
on Wed 06 Feb 2008 06:57 AM CST
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced
that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab more »
|
||
